Abstract Details

Title Daclizumab, a Potential Exit Strategy in MS Patients at High Risk for Natalizumab-Associated PML?

Topic Infectious Disease

Presentation(s) P5 - (-)

Poster/Presentation
Number 105

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Tobias Moser PRESENTER	Mr. Moser has nothing to disclose.
Christian Bsteh	No disclosure on file
Mihael V. Varosanec, MD (Buffalo NeuroImaging Analysis Center)	Dr. Varosanec has received research support from NIH.
Peter Wipfler	Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Peter Wipfler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Ferdinand Otto, MD, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Johann Sellner, MD, FAAN (Neurologie, LK Mistelbach)	Dr. Sellner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Boehringer, Celgene, Immunic, Merck, Novartis, Roche, Sanofi. Dr. Sellner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion, Biogen, Immunic, Merck, Novartis, Roche, Sanofi. Dr. Sellner has received personal compensation in the range of $0-$499 for serving as a Reviewer with Ethics Committtee.